Rhumbline Advisers Sage Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 87,323 shares of SAGE stock, worth $646,190. This represents 0.0% of its overall portfolio holdings.
Number of Shares
87,323
Previous 86,086
1.44%
Holding current value
$646,190
Previous $620,000
23.55%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding SAGE
# of Institutions
194Shares Held
45MCall Options Held
304KPut Options Held
117K-
Black Rock Inc. New York, NY5.22MShares$38.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.84MShares$35.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.59MShares$34 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$33 Million0.48% of portfolio
-
Rtw Investments, LP New York, NY3MShares$22.2 Million0.27% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $440M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...